|
|||
![]() |
|||
2008-01-11 12:27:00 CET 2008-01-17 12:29:09 CET REGLAMENTUOJAMA INFORMACIJA Inion Oyj - Articles of associationInion Pre-Close Trading Update and Board ChangeInion Pre-Close Trading Update and Board Change Tampere, Finland and Guildford, UK 11 January 2008…Inion Oy (LSE: IIN.L) (“Inion”), a company focused on the development of novel biodegradable medical implants, today provides an update on 2007 trading, ahead of its preliminary results announcement expected in March 2008. Based on the unaudited figures for the year to 31 December 2007, the Directors anticipate that revenues for 2007 will be approximately €5.2 million, which is in line with current market expectations. Chris Lee, Inion's CEO, said, “We have worked very hard during 2007 to establish the commercial expertise and appropriate distribution channels to drive dynamic growth in 2008 and beyond. I am pleased with the 2007 sales performance as it represents underlying customer demand, is sustainable and provides an excellent base on which to build the business.” Separately, Inion announces that Dr Auvo Kaikkonen, the Company's Chief Scientific Officer and Director, has resigned from the Board of Directors effective immediately. Dr Göran Ando, Inion's Non-executive Chairman, said, “I would like to thank Auvo for his contribution to the Board over the years since he co-founded Inion, and for his contribution to the strategic review process over the past year.” For further information, please contact: -------------------------------------------------------------------------------- | Inion Oy | Tel: +44 (0)1483 685390 | | Chris Lee, Chief Executive | | | Officer | | | Julien Cotta, Chief Financial | | | Officer | | -------------------------------------------------------------------------------- | Citigate Dewe Rogerson | Tel: +44 (0)207 638 9571 | | Mark Swallow / | | | David Dible | | -------------------------------------------------------------------------------- About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative biodegradable and bioactive implants in key target markets. The Company's target segments are Spine and Specialty Orthopaedics. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima™ family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004. The Company has an office in the UK and head office, R&D and production facilities in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. |
|||
|